← All trials
NCT06203132
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2024
- Primary completion
- Nov 30, 2026
- Completion date
- Nov 30, 2027
- First posted
- Jan 12, 2024
- Last posted
- Oct 30, 2024
- Enrollment
- 610
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of FranceLead sponsor
- MerckCollaborator
- Assistance Publique - Hôpitaux de ParisOfficial
- European and Developing Countries Clinical Trials Partnership (EDCTP)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.